Adamax vs Selank
A side-by-side research comparison of Adamax and Selank across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adamax | Selank |
|---|---|---|
| Full name | Adamax (Semax Analog Nootropic Peptide) | Selank (TP-7) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide | Research compound |
| Mechanism | As an ACTH/melanocortin-derived peptide analog, it is proposed to elevate BDNF and other neurotrophic factors, modulate the dopaminergic and serotonergic systems, and provide neuroprotection, similar to but reportedly more potent and longer-acting than Semax. | Modulates GABA-A allosteric sites, increases BDNF, stabilizes enkephalin degradation, and influences serotonin metabolism. Enhances IL-6 and Th1/Th2 balance. |
| Molecular weight | ~ (short peptide) | 751.9 Da |
| Half-life | Short (extended vs Semax) | 3-5 min (IV) / 15-30 min (intranasal) |
| Bioavailability | Intranasal or subcutaneous | Moderate (intranasal) |
| Typical dose | Low microgram-to-milligram range (research) | 250-750 mcg per spray dose |
| Frequency | 1-2x daily | 2-3x daily |
| Route | Intranasal or subcutaneous | Intranasal spray |
Adamax reported benefits
- Cognitive enhancement and focus
- Memory support
- Neuroprotection
- BDNF elevation (proposed)
- Mood support
Selank reported benefits
- Anxiolytic without sedation
- Improved memory/learning
- Cognitive flexibility
- Immune modulation
- BDNF upregulation
- No addiction
Related comparisons
Research and educational reference only. Not medical advice.